In line with the results in PARP inhibitor-/platinum-resistant ovarian cancer cells, TNBC cells with acquired resistance to PARP inhibitors also showed increased resistance to cisplatin compared with PARP inhibitor-sensitive parental cells (Extended Data Fig. 1d). The gene discussed is PARP1; the disease is ovarian carcinoma.